Tag: Alzheimer’s drug shows positive outcomes in genetic variant-based trial

Alzheimer’s drug shows positive outcomes in genetic variant-based trial

October 25, 2019

When US-based biotechnology company Biogen introduced an experimental drug to treat Alzheimer’s disease (AD), it was expected to become the first drug to successfully slow the disease’s progression, and would mark a great achievement in the medical world. Unfortunately, Biogen suspended those drug trials early this year after a “futility analysis” indicated patients on the […]

Continue Reading